DIR Return Create A Forum - Home
       ---------------------------------------------------------
       MS Speaks
  HTML https://msspeaks.createaforum.com
       ---------------------------------------------------------
       *****************************************************
   DIR Return to: TYSABRI (natalizumab)
       *****************************************************
       #Post#: 2390--------------------------------------------------
       (Abst.) PACTRIMS 2019: Trial of in-home natalizumab infusions
   DIR By: agate
       Date: February 6, 2019, 12:23 am
       ---------------------------------------------------------
       Biogen funded this study, presented at the 2019 PACTRIMS
       (Pan-Asian Committee on Treatment and Research in MS)
       conference, trying out in-home infusions of natalizumab:
       MS Treatment: Other Drugs
       Patients’ Perspectives on a Changed Model of Care from
       Out-patients to The Home for the Infusion of Natalizumab
       Juaton MS1, Cusack L1, Schultz TJ1, Thomas A2, Georgiou P3,
       Simon L3, Naidoo K4, Webb K5, Karnon J6, Ravindran J5
       1Adelaide Nursing School, University of Adelaide, Adelaide,
       Australia 5005; 2Post Op Care at Home (Pty Ltd), McLaren Vale,
       Australia 5171; 3Ambulatory Care Day Unit, Royal Adelaide
       Hospital, Adelaide, Australia 5005; 4Biogen Australia and New
       Zealand, North Ryde, Australia 2113; 5Neurology Department,
       Royal Adelaide Hospital, Adelaide, Australia 5005; 6School of
       Public Health, University of Adelaide, Adelaide, Australia 5005
       Conflict of interest: The research was Funded by Biogen
       Australia and New Zealand as investigator initiated research. Ms
       Anne Thomas is Director of Post-Op Care At Home (Pty Ltd). This
       organisation was sub-contracted to deliver the home care
       nursing. Ms Kerisha Naidoo is an employee of Biogen.
       Background: This paper presents the qualitative component of a
       study on the safety and clinical effectiveness, acceptability
       and cost effectiveness of home infusions of natalizumab for
       people with Multiple Sclerosis (MS). We compared the home
       nursing model of care with the usual care (an out-patient
       intravenous therapy service) in a randomised cross-over trial
       that included a qualitative component.
       Objective: The objective was to understand the experiences and
       perspectives of people who have received home infusions using
       the new model of care.
       Methods: This study was conducted using an exploratory
       descriptive methodology. Twelve of the 37 participants consented
       for a face-to-face interview. The transcripts were thematically
       analysed using the Braun and Clark approach.
       Results: The outcome from the interviews and analysis revealed
       eight subthemes, which were grouped into two main themes; ‘the
       experience’ and ‘convenience’. The findings indicated that being
       at home while receiving natalizumab infusions offers physical
       and emotional comfort for MS patients and their family. The
       benefits of delivering this infusion at home included no travel
       or car parking costs, no waiting in the hospital and comfort
       within the home environment. It was an easy and stress free
       experience for most participants. This study found that MS
       patients preferred receiving their natalizumab infusions at
       home.
       Conclusion: Patients’ voices must be used to inform
       patient-centred care. Home infusions of natalizumab are a safe
       alternative model of care and provide patient benefits such as
       flexibility, reduced costs and an improved patient experience.
       These findings should inform future healthcare delivery.
       *****************************************************
       Page 1 of 1